Search
larotrectinib
Indications: - tropomyosin receptor kinase (trk) fusion-positive cancers [1] * response rate 75% Mechanism of action: - tropomyosin receptor kinase (trk) inhibitor [1]General
small inhibitory antineoplastic agent (ib drug)References
- Drilon A, Laetsch TW, Kummar S et al Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731-739. February 22, 2018 PMID: 29466156 http://www.nejm.org/doi/full/10.1056/NEJMoa1714448